menu

MYR company blog

HomeMYR company blog
HomeMYR company blog

Press Release, Moscow, March 15th, 2012

Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program

Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds

Press Release, Moscow, October, 2014

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta

Press Release, Moscow, March 11th, 2014

MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF MYRCLUDEX B, FOR HBV

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.

Press Release, Moscow, March 15th, 2012

Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program

Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds

Press Release, Moscow, October, 2014

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta

Press Release, Moscow, March 11th, 2014

MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF MYRCLUDEX B, FOR HBV

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.